PDGF-DD is the ligand of NKp44 and can stimulate TNF-α and IFN-γ release in NK cells and contribute to cell cycle arrest in melanoma, ovarian cancer, and breast cancer by binding to NKp44. Here, NCR2 is linked to breast carcinoma.